Background: Black men and men with end-stage kidney disease have lower rates of treatment and higher mortality for prostate cancer. We studied the interaction of end-stage kidney disease (ESKD) with Black race for treatment rates and mortality for men with prostate cancer.
Methods And Results: We included 516 Black and 551 White men with ESKD before prostate cancer 22,299 Black men, and 141,821 White men without ESKD who were 40 years or older from the Surveillance, Epidemiology, and End-Results-Medicare data (2004-2016). All Black men with or without ESKD and White men with ESKD had higher prostate-specific antigen levels at diagnosis than White men without ESKD. Black men with ESKD had the lowest rates for treatment in both local and advanced stages of prostate cancer (age-adjusted risk ratio: 0.76, 95% Confidence Interval (CI): 0.71-0.82 for local stage and age-adjusted risk ratio: 0.82, 95% CI: 0.76-0.9 for advanced stages) compared to White men without ESKD. Compared to White men without ESKD, prostate cancer-specific mortality was higher in White men with ESKD for both local and advanced stages (age-adjusted hazard ratio: 1.8, 95% CI: 1.2-2.8 and HR: 1.6, 95% CI: 1.2-2.2) and it was higher for ESKD Black men only in advanced stage prostate cancer (age-adjusted hazard ratio: 2.4, 95% CI: 1.5-3.6).
Conclusion: Our findings suggest that having a comorbidity such as ESKD makes Black men more vulnerable to racial disparities in prostate cancer treatment and mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11106677 | PMC |
| http://dx.doi.org/10.1002/cam4.7027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology and early predictors of Fabry nephropathy: evaluation of long-term outcomes from a national Fabry centre.
J Nephrol
December 2024
The School of Medicine, Manchester Academic Health Sciences Centre, Manchester University, Manchester, UK.
Background: Fabry disease is a rare genetic lysosomal storage disorder, whereby the accumulation of sphingolipids consequently leads to kidney structural damage and dysfunction. We explored the epidemiology of chronic kidney disease (CKD) among patients with Fabry disease at a major UK referral centre in Greater Manchester serving over 7 million people, to inform early predictors of kidney disease and possible treatment planning.
Methods: Data were sourced from the electronic records of registered participants from November 2020 to February 2022 of adults diagnosed with Fabry disease, with at least 1 year of follow-up.
Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors.
Clin J Am Soc Nephrol
December 2024
Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Background: Acute kidney injury (AKI) increases the risk for chronic kidney disease (CKD). We aimed to identify combinations of clinical variables and biomarkers that predict long-term kidney disease risk after AKI.
Methods: We analyzed data from a prospective cohort of 723 hospitalized patients with AKI in the Assessment, Serial Evaluation, and Subsequent Sequelae of AKI (ASSESS-AKI) Study.
Clustering Analysis Identified Distinct Clinical Phenotypes among Hemodialysis Patients in Their Immunological Response to the BNT162b2 mRNA Vaccine against SARS-CoV-2.
Vaccines (Basel)
October 2024
IQVIA Laboratories Vaccines, Laval, QC H7V 3S8, Canada.
Article Synopsis
- The COVID-19 pandemic significantly impacted patients with end-stage kidney disease (ESKD), highlighting the importance of vaccination, particularly with mRNA vaccines, which improve outcomes like hospitalization and mortality.
- A study involving 117 fully vaccinated ESKD patients identified three distinct groups based on their immunological responses to the vaccine.
- These groups included women with long dialysis histories and men with diabetes showing low antibody levels, while a third group of non-diabetic middle-aged men had a strong positive vaccine response, allowing for personalized vaccination strategies.
Clinical Significance of Overlap Syndrome of Histologically Confirmed Lupus Nephritis with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
J Clin Med
September 2024
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
We applied the 2022 American College of Rheumatology/ European Alliance of Association for Rheumatology (ACR/EULAR) criteria for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) to patients histologically diagnosed with lupus nephritis (LN) to investigate the overall rate of and initial contributing factors to the reclassification of overlap syndrome of LN with AAV (OS-LN-AAV). We retrospectively reviewed the medical records of 1292 patients with systemic lupus erythematosus (SLE) and included 164 patients with LN in this study. Patient demographics, SLE manifestations, LN classes, and laboratory data, including ANCA levels, were recorded.
View Article and Find Full Text PDFSocioeconomic Inequalities Worsen the Risk of Death in CKD: A Population-Based Cohort Study in Italy.
Kidney360
September 2024
Department of Epidemiology of the Regional Health Service, ASL Roma 1, Rome, Italy.
Background: Few studies have explored the impact of socioeconomic position on chronic kidney disease (CKD). This study aims to fill this gap using a large Italian cohort of CKD patients.
Methods: We analyzed a cohort of incident CKD cases from the Lazio regional Health Information System from 1 January 2012 to 31 December 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!